Mahzi Therapeutics Announces FDA Rare Pediatric Disease Designation for MZ-1866 Investigational Therapy for Pitt Hopkins Syndrome
<p>MZ‑1866 Phase 1/2 UNITE Study is now more than 50% enrolled SOUTH SAN FRANCISCO, Calif., Aug. 25, 2026 /PRNewswire/ -- Mahzi Therapeutics Inc., a clinical-stage biotechnology company developing precision therapies for neurogenetic disorders, today announced that the U.S. Food and Drug...</p>
Read original article ↗
Related Articles
NSF Launches 3 New Science and Technology Centers with $90M Investment
Aug. 26, 2026 — The U.S. National Science Foundation is investing $90 million over five years to support three new NSF S
Ox Alpha is a multimodal GLM model by Z.ai: Apple Mini and Studio desktops target AI power users
Perplexity moves its computer use agent to on-device models. OpenAI’s Jalapeño may be faster than Nvidia’s best chips. I
Pinea Pi Opens Pre-Orders: Defining the Edge AI Device for the AI-Native Generation
NEW YORK, Aug. 26, 2026 /PRNewswire/ -- Pinea Pi, the AI-native hardware pioneer, today announced that its first edge AI
Sheriff's Agency Selects SuperCom After Receiving Direct Referral from an Existing County Customer NEW YORK, Aug. 26, 20